Liquidia Corp

Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes treatments for patients with severe respiratory and vascular diseases, focusing on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company’s primary offerings include Yutrepia, an inhaled dry-powder treprostinil therapy, and a generic treprostinil injection marketed in partnership with Sandoz. Liquidia promotes its products to healthcare professionals, notably pulmonologists and cardiologists, as well as specialty pharmacies and medical distributors.

The company operates primarily within the United States, where it maintains a targeted commercial sales force calling on specialized medical centers. Liquidia conducts manufacturing and research operations at a 45,000-square-foot facility in Morrisville, North Carolina, and holds a lease for an additional 70,131-square-foot site in Morrisville. Globally, the company conducts clinical trials across more than 100 sites in at least 20 countries.

Summary of the business section of Liquidia's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 216 employees.”